10x Genomics Inc. (TXG)
10x Genomics Inc. (TXG) Stock Price, Analysis & Data
| Bid | 42.25 |
| Market Cap | 7.52B |
| Revenue (ttm) | 616.91M |
| Net Income (ttm) | -75.13M |
| Beta | 2.04 |
| EPS (ttm) | -0.59 |
| PE Ratio (ttm) | n/a |
| Forward PE | 284.02 |
| P/B (ttm) | 9.15 |
| P/S (ttm) | 12.20 |
| Earnings Date | Nov 5, 2026 |
| Ask | 72.65 |
| Volume | 3,296,226 |
| Avg. Volume (20D) | 3,277,491 |
| Open | 58.61 |
| Previous Close | 58.48 |
| Day's Range | 56.56 - 59.37 |
| 52-Week Range | 11.16 - 60.69 |
| Analyst | Buy |
| Price Target | 50 (-13.42%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About TXG
10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instr...
Financial Performance
In 2025, 10x Genomics's revenue was 642.82M, an increase of 5.25% compared to the previous year's 610.78M. Earnings were -43.54M, a decrease of -76.16%.
Financial StatementsAnalyst Forecast
According to 13 analyst ratings, the average rating for TXG stock is "Buy". The 12-month stock price forecast is 50, which is downside of 13.42% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
